>>> US Gapping down

Gapping down
Other news:
  • BIOA -70.1% (Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity)
  • COGT -21.3% (Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis; announces updated clinical results from SUMMIT, showcasing powerful symptomatic improvement in nonadvanced systemic mastocytosis patients)
  • AGIO -7.5% (Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat)
  • ENTA -7.4% (Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus)
  • RIOT -6.4% (announces proposed private offering of $500 million of convertible senior notes)
  • MRUS -5.6% (Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC)
  • OBIO -5.2% (Announces AVIM Therapy Program Presentations at ICI Meeting)
  • MOLN -4% (Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024)
  • DDOG -3.3% (announces proposed private offering of $775 million of convertible senior notes)
  • RMBL -2.4% (entered into that certain Floor Plan Financing Agreement)
  • NVDA -1.8% (China investigating NVDA over anti-monopoly laws, according to Bloomberg)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • MOMO +5.5%,
Other news:
  • IPHA +32% (Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma)
  • CCCC +16.7% (Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader)
  • PRTC +10.9% (Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting)
  • AFMD +10.7% (Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients)
  • SMCI +9.4% ( Announces Receipt of Extension from Nasdaq Stock Market)
  • DADA +9.2% (increases the pool size of its share incentive plan and provides class action update)
  • WDAY +9.1% (to join S&P 500)
  • PLTR +7.8% (Anduril and Palantir to Accelerate AI Capabilities for National Security)
  • CRGX +7.7% (files mixed securities shelf offering)
  • SVRE +6.6% (files for 3 mln ADS offering by selling shareholder)
  • ACLX +6.5% (Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition)
  • APO +6.1% (to join S&P 500)
  • BEAM +6% (Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting; Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting)
  • OMI +4.9% (awarded a maximum $4.5 bln modification to Defense Logistics Agency contract)
  • NOAH +4.8% (Showcases Global Expansion and Investment Product Leadership at 2024 Corporate Open Day)
  • KURA +4.4% (Kura Oncology and Kyowa Kirin (KYKOY) Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting)
  • DOW +4% (partners with Macquarie Asset Management to launch Diamond Infrastructure Solutions)
  • TX +3.8% (affirmed Friday that the Brazilian Court Confirms Ternium's Obligation to Pay Indemnification in connection with its 2012 Acquisition of a Participation in Usiminas; the Decision is subject to further appeals)
  • SNDX +3.5% (Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting)
  • TASK +3.5% (approved a one-year extension of its share repurchase authorization, extending the previously authorized $200 million authorization through December 31, 202)
  • THTX +3.5% (announces preliminary tolerability and efficacy data from Phase 1b, dose-ranging trial of sudocetaxel zendusortide in patients with advanced ovarian cancer) M +2.9% (Barington Capital Group calls on Macy's to make changes to its capital allocation plan to improve shareholder value)
  • ADCT +2.6% (The Lancet Haematology publication of data from investigator-initiated trial evaluating ZYNLONTA in combination with rituximab to treat relapsed/refractory follicular lymphoma)
  • OLMA +2.4% (FDA has cleared its Investigational New Drug application for OP-3136)
  • GLPG +2.3% (reports new results from ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with relapsed/refractory non-hodgkin lymphoma)
  • ANGO +2.3% (receives FDA clearance for The NanoKnife System for prostate tissue ablation)
  • BPMC +2.1% (Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting)
  • PLX +1.8% (Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa)
  • ZVRA +1.7% (announces organizational changes)
  • CRBP +1.6% (Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors)
  • AIN +1.2% (increases quarterly dividend by 4% to $0.27/share)
  • AES +1% (increases quarterly dividend by 2%)
  • IDXX +1% (announces that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five mln additional shares of the Company's common stock)

>>> Europe : Brokers Upgrades & Downgrades - 9th of December 2024 V3(++)

>>> Up
* 1&1 Raised to Buy at Goldman; PT 15 euros
* ABB Raised to Equal-Weight at Morgan Stanley; PT 48 Swiss francs
* AJ Bell Raised to Buy at Shore Capital (+)
* BASF Raised to Buy at M.M. Warburg; PT 52.60 euros (++)
* Berkeley Raised to Add at Peel Hunt; PT 4,400 pence (++)
* BNY Mellon Raised to Overweight at Morgan Stanley; PT $94
* Enento Group Raised to Accumulate at Inderes; PT 19 euros
* Equinor Raised to Overweight at JPMorgan; PT 330 kroner
* Groupe LDLC Raised to Hold at TP ICAP Midcap; PT 9.80 euros (+)
* INWIT Raised to Buy at Goldman; PT 13.50 euros
* Jefferies Raised to Overweight at Morgan Stanley; PT $97
* LSE Group PT Raised to 13,500 pence at Jefferies
* McCormick Raised to Buy at Jefferies; PT $91
* Moelis & Co Raised to Overweight at Morgan Stanley; PT $92
* Neste Raised to Neutral at JPMorgan; PT 17 euros
* Nokia Raised to Overweight at JPMorgan; PT 6.05 euros
* Nokia ADRs Raised to Overweight at JPMorgan; PT $6.35
* Northern Trust Raised to Equal-Weight at Morgan Stanley; PT $127
* Prodways Raised to Strong Buy at Portzamparc; PT 74 euro cents (+)
* Reddit Raised to Overweight at Morgan Stanley; PT $200
* Repsol Cut to Underweight at JPMorgan; PT 12.50 euros
* Rexel Raised to Overweight at Morgan Stanley; PT 29 euros
* Rockwell Automation Raised to Overweight at KeyBanc; PT $345
* SAP PT Raised to 300 euros from 260 euros at Citi
* State Street Raised to Overweight at Morgan Stanley; PT $139
* Schwab Raised to Overweight at Barclays; PT $95
* Team17 Raised to Buy at Jefferies; PT 360 pence
* Tenaris Raised to Buy at Jefferies; PT 22 euros
* Tenaris ADRs Raised to Buy at Jefferies; PT $47
* Vertex Pharmaceuticals Raised to Buy at Jefferies; PT $550
* Weir Group PLC/The Raised to Overweight at Morgan Stanley

>>> Down
* Ashtead Cut to Hold at Deutsche Bank (+)
* Bank of America Cut to Equal-Weight at Morgan Stanley; PT $55
* Baltic Classifieds Group Cut to Hold at Deutsche Bank (+)
* Biogen Cut to Hold at Jefferies; PT $180
* DocMorris AG Cut to Market Perform at ZKB (+)
* Enea Cut to Neutral at Citi; PT 12.50 zloty
* Epiroc Cut to Underweight at Morgan Stanley; PT 182 kronor
* Frasers Group Cut to Equal-Weight at Barclays; PT 760 pence
* Freenet Cut to Sell at Goldman; PT 28.50 euros
* Iveco Cut to Hold at Deutsche Bank (+)
* Kone Cut to Underweight at Morgan Stanley; PT 44 euros
* Lazard Inc Cut to Equal-Weight at Morgan Stanley; PT $63
* Neste Cut to Neutral at Citi; PT 16 euros
* Porsche SE Cut to Sell at UBS; PT 32 euros (++)
* Signify Cut to Equal-Weight at Morgan Stanley; PT 25 euros
* Spirax Raised to Overweight at Morgan Stanley; PT 8,500 pence
* STMicro Cut to Neutral at JPMorgan; PT 30 euros
* Trainline Cut to Neutral at UBS; PT 490 pence (++)
* Vodafone ADRs Cut to Neutral at Goldman; PT $10.45
* Vodafone Cut to Neutral at Goldman; PT 83 pence

>>> Initiation
* Alphabet Rated New Buy at SPDB Intl HK; PT $202
* Amazon Rated New Buy at SPDB Intl HK; PT $263
* Bentley Systems Rated New Neutral at JPMorgan; PT $52
* Meta Platforms Rated New Buy at SPDB Intl HK; PT $763
* Pharming ADRs Rated New Buy at Jefferies; PT $14
* Pharming Rated New Buy at Jefferies; PT 1.40 euros
* Serica Rated New Buy at Canaccord; PT 195 pence (+)
* Sunrise Communications/old Rated New Sell at Goldman

>>> Call
* Market Is Too Bearish on ASML Stock, JPMorgan Analysts Say
* Cash Flow Efficacy Key For Big Oil, Equinor Upgraded at JPMorgan
* Deutsche Bank Strategists Say Equity Exposure Is Not Extreme (+)
* DocMorris Indicated Lower as ZKB Cuts, Citing Liquidity Concerns
* HelloFresh Stock ‘Unjustly’ Pressured by Labor Claims: Jefferies (++)
* HMS Networks Gains as DNB Sees Organic Order Recovery in 2025 (++)
* LSE’s PT Raised to Joint Street-High at Jefferies on Data Growth (+)
* Morgan Stanley Sees ‘Year of Two Halves’ in Europe Capital Goods
* Neste Downgraded to Neutral at Citi on Tougher US Landscape
* Oppenheimer’s Stoltzfus New Top S&P 500 Bull With 7,100 Target
* Pharming Rises as Jefferies Adds to Clean Sweep of Buy Views (++)
* Regional Convergence Still Lacks Catalyst: JPMorgan Strategists (+)
* Swedencare Jumps as Dagens Industri Recommends to Buy (++)
* US Stock Positioning Slips; Some Investors See Big Pullback: RBC (++)

WSJ : Activist Investor to Push Macy’s for Changes, Including New Real-Estate Un

Activist Investor to Push Macy’s for Changes, Including New Real-Estate Unit
Barington is working with Thor Equities and wants the company to slash spending

Activist investor Barington Capital has built a position in Macy’s M -0.12%decrease; red down pointing triangle and plans to push the department-store operator to make changes to boost its slumping stock, including the creation of a separate real-estate unit within the company.

Barington plans to disclose its position in a PowerPoint presentation to Macy’s shareholders that was viewed by The Wall Street Journal and is expected to be published on its website later Monday. The exact size of the stake couldn’t be learned.

Barington has teamed up with property-owner Thor Equities on its investment, according to the presentation.

The investors believe Macy’s shares are significantly undervalued and that the company should create a real-estate subsidiary that focuses on maximizing the value of its owned and leased locations. They believe Macy’s real estate alone is worth between $5 billion and $9 billion, which is more than the company’s current market value.

Barington and Thor are also pushing Macy’s to consider strategic alternatives for two other chains it owns—Bloomingdale’s and Bluemercury. The investors see those as luxury brands that would trade at a higher multiple on their own.

They are further asking Macy’s to cut capital expenditures to between 1.5% and 2% of total sales—from about 4%—and buy back at least $2 billion to $3 billion in stock over the next three years. All told, these changes could help boost Macy’s shares by as much as 200% over the next three years, the presentation said.

Barington and Thor also want their representatives added to Macy’s board, the presentation says.

Department-store troubles
Macy’s had a market value of about $4.6 billion as of Friday, with its stock down 18% this year at $16.43. In 2015, Macy’s stock traded as high as $70 a share before competition from nimbler digital retailers took a toll, among other challenges.

This isn’t Macy’s first brush with an activist investor. The company earlier this year averted a fight for control of its board. It added two new directors while resisting a takeover bid.

In July, Macy’s terminated talks with two investors—Arkhouse Management and Brigade Capital Management—that had offered to buy the company for about $6.9 billion, ending a monthslong effort to take Macy’s private. (It was the second time the duo had raised their buyout offer.)

Macy’s has been targeted by other activists. Starboard Value built a stake in 2015 and pushed the company to spin off its real-estate assets, including its famous Herald Square location in New York City. Jana Partners also bought up Macy’s stock in 2021 and pushed for a separation of its online business.

Macy’s Chief Executive Officer Tony Spring, who ascended to the top job earlier this year, is fighting to turn around sluggish sales by improving the customer experience and decluttering shops.

The company has been trimming its store count and focusing on remodels and opening newer, smaller formats. Today it counts more than 470 of its namesake Macy’s locations, more than 30 Bloomingdale’s shops and over 160 Bluemercury stores, according to its website.

More changes demanded
Late last month, the company delayed its quarterly results after it found an employee hid up to $154 million in corporate delivery expenses over several years, prompting an internal investigation. (Macy’s is due to report quarterly results this Wednesday and has said it would provide details on its findings then.)

Barington said in the presentation that Macy’s should look to Dillard’s, another publicly traded department-store chain, as a model for keeping expenses in check and delivering returns to shareholders. Dillard’s stock is up about 10% year to date.

Barington was founded in 2000 by James Mitarotonda, who has sat on the board of companies including Pep Boys and Avon Products. The firm has successfully pushed for changes at retailers including L Brands—which broke up into Victoria’s Secret and Bath & Body Works—and underwear maker Hanesbrands.

Thor was founded in 1986 by Joseph Sitt, who also launched plus-size apparel retailer Ashley Stewart. It owns properties across New York, London and other major cities. Its other retail investments have included the surfing-inspired brand Hurley and lifestyle clothing line Madhappy.

Activist investors typically kick into high gear this time of year, when many companies begin accepting shareholder nominations ahead of their annual meetings in the spring.

>>> Weekend Reading Summary

Weekend Reading Summary
Macro Related:
  • President-elect Trump in interview says he plans sweeping actions when he takes office including extending tax cuts, large deportations, and tariffs. He said he would not fire Fed Chairman Jerome Powell. NBC News
  • Ukrainian President Volodymyr Zelenskyy says he had a "good and productive" meeting with President-elect Trump. Mr. Trump called for an "immediate ceasefire" and told Russian President Putin it is "time to act." Politico
  • Syria President Bashar al-Assad resigns and leaves the country as rabels took control of Syria's capital (USO, XLE). NY Times
  • Chinese leaders change stance on monetary policy to "moderately loose" from "prudent" (FXI). FT
  • South Korean President Yoon Suk Yeol survived impeachment vote (EWY). NY Times
Stock Specific:
  • Cautious view on MicroStrategy (MSTR). Barron's
  • Paramount's (PARA) merger with Skydance Media is facing new roadblocks. NY Post
  • Apple (AAPL) mulling bringing cell phone service to Macs for the first time. Bloomberg
  • China resumes gold purchases (GLD, GDX, NEM, GOLD, AEM). Bloomberg
  • Los Angeles area could have power cuts due to wildfires (PCG). Bloomberg
  • Tickets for Disney's (DIS) first Asia cruise ship go on sale next week. Bloomberg
  • President-elect Trump says he would consult governors about increasing minimum wage (WMT, TGT, DLTR, FIVE, DG, MCD, WEN). NBC News
  • President-elect Trump says RFK will investigate discredited links between vaccines and autism. Mr. Trump was also critical of PBMs (PFE, BNTX, MRNA, NVAX, CVS, UNH, CI, WBA). NBC News
  • Advanced artificial intelligence chips were cleared for export to UAE (NVDA, MSFT). Axios
  • President-elect Trump says he would say in NATO as long as they pay their bills and Ukraine should prepare to receive less aid (LMT, NOC, GD, LHX). NBC News
  • Omnicom (OMC) in discussions to acquire Interpublic (IPG). WSJ
  • Apple (AAPL) and Sony (SONY) discussed partnership on gaming controllers. Bloomberg
  • VinFast (VFS) Vietnam plant will start operating by July. Bloomberg
  • Aides to President-elect Trump have contacted Meta (META), Snapchat (SNAP), and Google (GOOG, GOOGL) over online sale of drugs. The Information
  • Boeing (BA) whistleblower says company did not keep track of non-conforming parts. 60 Minutes
  • India wants Supreme Court hearing on Amazon (AMZN) / Flipkart issues. Reuters
  • Labor department investigating child labor claims at HelloFresh (HELFY). ABC News

>>> Europe : Brokers Upgrades & Downgrades - 9th of December 2024 V2(+)

>>> Up
* 1&1 Raised to Buy at Goldman; PT 15 euros
* ABB Raised to Equal-Weight at Morgan Stanley; PT 48 Swiss francs
* AJ Bell Raised to Buy at Shore Capital (+)
* BNY Mellon Raised to Overweight at Morgan Stanley; PT $94
* Enento Group Raised to Accumulate at Inderes; PT 19 euros
* Equinor Raised to Overweight at JPMorgan; PT 330 kroner
* Groupe LDLC Raised to Hold at TP ICAP Midcap; PT 9.80 euros (+)
* INWIT Raised to Buy at Goldman; PT 13.50 euros
* Jefferies Raised to Overweight at Morgan Stanley; PT $97
* LSE Group PT Raised to 13,500 pence at Jefferies
* McCormick Raised to Buy at Jefferies; PT $91
* Moelis & Co Raised to Overweight at Morgan Stanley; PT $92
* Neste Raised to Neutral at JPMorgan; PT 17 euros
* Nokia Raised to Overweight at JPMorgan; PT 6.05 euros
* Nokia ADRs Raised to Overweight at JPMorgan; PT $6.35
* Northern Trust Raised to Equal-Weight at Morgan Stanley; PT $127
* Prodways Raised to Strong Buy at Portzamparc; PT 74 euro cents (+)
* Reddit Raised to Overweight at Morgan Stanley; PT $200
* Repsol Cut to Underweight at JPMorgan; PT 12.50 euros
* Rexel Raised to Overweight at Morgan Stanley; PT 29 euros
* Rockwell Automation Raised to Overweight at KeyBanc; PT $345
* SAP PT Raised to 300 euros from 260 euros at Citi
* State Street Raised to Overweight at Morgan Stanley; PT $139
* Schwab Raised to Overweight at Barclays; PT $95
* Team17 Raised to Buy at Jefferies; PT 360 pence
* Tenaris Raised to Buy at Jefferies; PT 22 euros
* Tenaris ADRs Raised to Buy at Jefferies; PT $47
* Vertex Pharmaceuticals Raised to Buy at Jefferies; PT $550
* Weir Group PLC/The Raised to Overweight at Morgan Stanley

>>> Down
* Ashtead Cut to Hold at Deutsche Bank (+)
* Bank of America Cut to Equal-Weight at Morgan Stanley; PT $55
* Baltic Classifieds Group Cut to Hold at Deutsche Bank (+)
* Biogen Cut to Hold at Jefferies; PT $180
* DocMorris AG Cut to Market Perform at ZKB (+)
* Enea Cut to Neutral at Citi; PT 12.50 zloty
* Epiroc Cut to Underweight at Morgan Stanley; PT 182 kronor
* Frasers Group Cut to Equal-Weight at Barclays; PT 760 pence
* Freenet Cut to Sell at Goldman; PT 28.50 euros
* Iveco Cut to Hold at Deutsche Bank (+)
* Kone Cut to Underweight at Morgan Stanley; PT 44 euros
* Lazard Inc Cut to Equal-Weight at Morgan Stanley; PT $63
* Neste Cut to Neutral at Citi; PT 16 euros
* Signify Cut to Equal-Weight at Morgan Stanley; PT 25 euros
* Spirax Raised to Overweight at Morgan Stanley; PT 8,500 pence
* STMicro Cut to Neutral at JPMorgan; PT 30 euros
* Vodafone ADRs Cut to Neutral at Goldman; PT $10.45
* Vodafone Cut to Neutral at Goldman; PT 83 pence

>>> Initiation
* Alphabet Rated New Buy at SPDB Intl HK; PT $202
* Amazon Rated New Buy at SPDB Intl HK; PT $263
* Bentley Systems Rated New Neutral at JPMorgan; PT $52
* Meta Platforms Rated New Buy at SPDB Intl HK; PT $763
* Pharming ADRs Rated New Buy at Jefferies; PT $14
* Pharming Rated New Buy at Jefferies; PT 1.40 euros
* Serica Rated New Buy at Canaccord; PT 195 pence (+)
* Sunrise Communications/old Rated New Sell at Goldman

>>> Call
* Cash Flow Efficacy Key For Big Oil, Equinor Upgraded at JPMorgan
* Deutsche Bank Strategists Say Equity Exposure Is Not Extreme (+)
* DocMorris Indicated Lower as ZKB Cuts, Citing Liquidity Concerns
* LSE’s PT Raised to Joint Street-High at Jefferies on Data Growth (+)
* Morgan Stanley Sees ‘Year of Two Halves’ in Europe Capital Goods
* Neste Downgraded to Neutral at Citi on Tougher US Landscape
* Oppenheimer’s Stoltzfus New Top S&P 500 Bull With 7,100 Target
* Regional Convergence Still Lacks Catalyst: JPMorgan Strategists (+)

>>> Stoxx 600 Pre-Market Indications

  • Banco BPM (BPM TH) +4.4%
    • Credit Agricole Moves to Raise Banco BPM Stake Amid UniCredit Bid
  • Monte Paschi (MPI0 TH) +3.7%
  • Bayer (BAYN TH) +2.7%
    • Bayer AG: SILAL and Bayer Advance Agricultural Innovation Partnership with Comprehensive Memorandum of Understanding
  • Equinor (DNQ TH) +1.9%
    • Equinor Closes $2b Deals Exiting Nigeria, Azerbaijan Upstream
  • Diageo (GUI TH) +1.4%
  • Aena (A44 TH) +1.4%
  • Campari (58H TH) +1.4%
  • Publicis (PU4 TH) +1.2%
  • WPP (0WP TH) +1.2%
  • Zealand Pharma (22Z TH) +1.2%
  • Telefonica (TNE5 TH) -1.5%
  • UniCredit (CRIN TH) -1.5%
    • Credit Agricole Moves to Raise Banco BPM Stake Amid UniCredit Bid
  • NIBE Industrier (NJB TH) -1.5%
  • Repsol (REP TH) -1.6%
    • Cash Flow Efficacy Key For Big Oil, Equinor Upgraded at JPMorgan
  • Ryanair (RY4C TH) -1.9%
    • Europe Airlines’ Normalizing Capacity Growth Raises Yield Stakes
  • Freenet (FNTN TH) -2%
    • Freenet Cut to Sell at Goldman; PT 28.50 euros
  • STMicro (SGM TH) -2%
    • STMicro Cut to Neutral at JPMorgan; PT 30 euros
  • Vodafone (VODI TH) -2.3%
    • Vodafone ADRs Cut to Neutral at Goldman; PT $10.45
  • EasyJet (EJT1 TH) -2.4%
  • Kingfisher (KFI1 TH) -2.9%